Gilde-backed BG Medicine raises $40m

In a series-D financing round, BG Medicine has raised $40m from existing shareholders including Flagship Ventures and Gilde as well as new investors Legg Mason Capital Management, GE Asset and SMALLCAP World Fund.

BG Medicine has developed biomarkers for clinically and commercially important diseases and treatments. From these biomarker discoveries, the company has developed a range of diagnostic products designed to predict a patient's response to a drug therapy. The lead products concern cardio-vascular diseases.

The company is based in the US but has a significant subsidiary in the Netherlands.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Industry
• Benelux